American Journal of Cardiovascular Drugs

, Volume 12, Issue 4, pp 255–262

Comparison of Hyperkalemic Risk in Hospitalized Patients Treated with Different Angiotensin Receptor Blockers

A Retrospective Cohort Study Using a Korean Clinical Research Database

Authors

  • Inwhee Park
    • Department of NephrologyAjou University School of Medicine
  • Seung Soo Sheen
    • Department of Pulmonary and Critical Care MedicineAjou University School of Medicine
  • Hong-Seok Lim
    • Department of CardiologyAjou University School of Medicine
  • Dukyong Yoon
    • Department of Biomedical InformaticsAjou University School of Medicine
  • Man Young Park
    • Department of Biomedical InformaticsAjou University School of Medicine
  • Suk-Hyang Lee
    • College of PharmacyAjou University
  • Gyu-Tae Shin
    • Department of NephrologyAjou University School of Medicine
  • Heungsoo Kim
    • Department of NephrologyAjou University School of Medicine
    • Department of Biomedical InformaticsAjou University School of Medicine
Original Research Article

DOI: 10.1007/BF03261834

Cite this article as:
Park, I., Sheen, S.S., Lim, H. et al. Am J Cardiovasc Drugs (2012) 12: 255. doi:10.1007/BF03261834

Abstract

Background and Aim

Clinical use of angiotensin II type 1 receptor antagonists (angiotensin receptor blockers [ARBs]) is associated with hyperkalemia as an adverse drug reaction. Although it has significant clinical implications, the incidence and relative risks of hyperkalemia with various ARBs have not yet been fully evaluated. The purpose of this study was to determine the risk of hyperkalemic events in hospitalized patients treated with different ARBs and to compare the risk among them.

Methods

We constructed a retrospective cohort composed of hospitalized adult patients who took ARBs in a single tertiary teaching hospital between April 2004 and March 2010. We estimated the incidence of hyperkalemia (serum potassium level >5.5 mEq/L) with various ARBs, and then compared the risk between them using a multivariate Cox proportional hazard model based on age, sex, Charlson co-morbidity score, baseline serum potassium, underlying diseases, and concomitant drugs.

Results

We identified 6992 evaluable intervals from 5449 patients treated with one of the seven ARBs during hospitalization over the 71-month study period with 2521.6 patient-months. We found 381 hyperkalemic events (5.4%) during the study period and an overall event rate of 15.1/100 patient-months. Moderate to fatal hyperkalemia was relatively rare (>6.0 mEq/L, 2.1% [moderate]; >6.5 mEq/L, 0.9% [severe]; >7.0 mEq/L, 0.3% [fatal]). After adjustment for covariates, telmisartan showed a lower risk of hyperkalemia (hazard ratio 0.67; 95% confidence interval 0.51, 0.89) compared with all other ARBs.

Conclusion

The risk of hyperkalemic events in hospitalized patients treated with different ARBs was defined. Telmisartan showed a relatively lower hyperkalemic risk profile in hospitalized patients compared with other ARBs.

Copyright information

© Springer International Publishing AG 2012